COVID-19 Testing Explained
Roche Covid-19 response
On Wednesday 11th March the World Health Organization (WHO) declared a pandemic in response to the COVID-19 outbreak. This is a serious health situation and we extend our sympathies to people who have lost loved ones, to patients and healthcare professionals. We recognise that the public and private sectors across the globe need to work together to help effectively manage this developing situation.
The COVID-19 pandemic continues to evolve rapidly and we are doing everything we can to contribute. Our people are working day and night to increase wherever possible the supply of key tests and medicines, we are partnering with local authorities and organisations to support front line healthcare providers, and we are continuing to help make sure that patients - many of whom have very serious illnesses - receive the treatment and care they need.
Our contribution to the response focuses on our existing strengths and capabilities:
We are committed to providing testing solutions for the world’s most challenging healthcare emergencies. Our emergency response teams worked rapidly to develop a diagnostics test which was granted Emergency Use Authorization by the US Food and Drug Administration. It is also available in markets accepting the CE mark.
Investigating treatment options
While there are currently no approved treatment options for the treatment of COVID-19, Roche is actively involved in understanding the potential of our existing portfolio. Roche has confirmed initiation of a clinical trial, and is also collecting and compiling data from other, independently led, clinical trials that are taking place around the world.
Under exceptional conditions around the world, colleagues at Roche are doing everything they can to ensure that patients – many of whom have very serious illnesses – receive the treatment and care they need and that we keep a complex value chain of diagnostics and medicines going.
While we respond to COVID-19, we also continue to deliver medicines and diagnostics wherever possible for patients across a broad range of other disease areas under exceptional conditions.
Roche is working with the highest priority and urgency to mitigate any current and future supply disruptions. However, some delays and disruptions may arise due to unprecedented demand, the current transportation and travel restrictions, and potential for workforce capacity limitations in highly impacted COVID-19 locations.
Public and private sectors across the globe must work together to address this challenge.
All across the world, we are working together with partners in the industry, our customers, NGOs, governments and regulatory bodies to ensure we maximise the impact of our work to contain the novel coronavirus. We call on governments to keep borders and global supply lines open for medical equipment and supplies, so that medicines and tests can reach the people who need them most.
In these exceptional times, Roche stands shoulder to shoulder with governments, healthcare providers and all those working to overcome the pandemic.
The most important thing at this time is our own individual responsibility to stop infection and to flatten the curve. It is really critical at the moment because it gives relief to healthcare systems to cope with patients who are really in need of aid.
Severin Schwan, CEO of the Roche Group